FDA weighs new mRNA-based flu shot from Moderna

The FDA is preparing to make a decision on Moderna's mRNA-based flu vaccine, which would represent a groundbreaking first for this technology in the flu shot market. The approval could have significant implications across the biotech industry, particularly for mRNA vaccine applications beyond COVID-19.